Form 4 for KROS Keros Therapeutics, Inc.
Accepted 2026-04-06 16:15:08 ET · period of report 2026-04-02 · accession 0001732369-26-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-04-06 16:15 | 2026-04-02 | KROS | Seehra Jasbir | CEO, Dir | M - OptEx | $0.3 | +55.0K | 440.7K | +14% | +$16.5K |
| D | 2026-04-06 16:15 | 2026-04-02 | KROS | Seehra Jasbir | CEO, Dir | M - OptEx | $0.00 | -55.0K | 197.4K | -22% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-02 | M | A | 55,000 | $0.3 | 440,708 | D | — | — | |
| 2 | Derivative | Employee Stock Option (Right to Buy) | 2026-04-02 | M | D | 55,000 | $0.00 | 197,444 | D | $0.3 · — to 2028-03-25 | 55,000 Common Stock | (F1) Immediately exercisable. |